Small Stocks, Big Money™

Enlivex Therapeutics (Nasdaq: ENLV) has received authorization from the Danish Medicines Agency to initiate the Phase II stage of its Phase I/II trial for Allocetra™, targeting moderate to severe knee osteoarthritis. This follows a successful Phase I safety run-in, with the independent DSMB recommending progression. The Phase II trial will be a double-blind, placebo-controlled study evaluating the efficacy and safety of Allocetra™ injections, with key assessments on joint pain and function at three, six, and 12 months post-treatment. Osteoarthritis affects over 300 million people globally, with a critical need for new treatments.

Gorilla Technology (Nasdaq: GRRR) and CS Energy have formed a strategic partnership to accelerate the development of AI-driven smart and sustainable cities across Thailand and Southeast Asia. Leveraging Gorilla's expertise in AI, IoT, and cybersecurity with CS Energy’s energy infrastructure solutions, the collaboration will focus on smart energy management, EV infrastructure, and enhanced urban security. By integrating cutting-edge technologies, the partnership aims to create scalable, energy-efficient urban environments that support the region's sustainability goals and meet growing energy demands.

Alta Global Group (NYSE American: MMA) has appointed fitness industry legends Mark Mastrov, founder of 24-Hour Fitness, and Adam Sedlack, CEO of UFC Gym, to its Advisory Board. Their expertise will be key as Alta expands globally, following its recent partnership to introduce its programs in 150+ UFC gyms worldwide. This strategic move strengthens Alta’s mission to convert MMA fans into participants, backed by the recent addition of Conor McGregor as global ambassador. Mastrov and Sedlack join a prestigious board as Alta enters a new phase of growth in the combat sports sector.

Trinity Biotech (Nasdaq: TRIB) has acquired Metabolomics Diagnostics, a deep-tech company specializing in AI-powered diagnostic solutions, to strengthen its presence in maternal health. The acquisition will enable Trinity to commercialize PrePsia, an innovative test that predicts preeclampsia risk as early as the 12th week of pregnancy, through its New York-based Immco reference lab starting in 2025. This strategic move leverages advanced machine learning and mass spectrometry technology, aligning with Trinity’s broader diagnostic capabilities to address critical maternal health challenges globally. The acquisition is valued at approximately $1.3 million.